1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemED-Lin-MC3-DMACat. No.: HY-112251CAS No.: 1224606-06-7分式: CHNO分量: 642.09作靶點: Others作通路: Others儲存式: Pure form -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 43.33 mg/mL (67.48 mM)Ethanol : 16.67 mg/mL (

2、25.96 mM; Need ultrasonic)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.5574 mL 7.7871 mL 15.5741 mL5 mM 0.3115 mL 1.5574 mL 3.1148 mL10 mM 0.1557 mL 0.7787 mL 1.5574 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 D-Lin-MC3-DMA種陽離脂

3、質體, 種有效的遞送 siRNA 載體。前泛應于腫瘤基因治療研究中。體內研究Lipid nanoparticles (LNPs) containing distearoylphosphatidlycholine (DSPC), and ionizableamino-lipids suchas dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA) are potent siRNA delivery vehicles in vivo.LNP-siRNA systems optimize to achieve maximum gene sil

4、encing potency in hepatocytesfollowing IV1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEadministration in mice contain DLin-MC3-DMA (MC3), DSPC, cholesterol and a polyethyleneglycol (PEG)-lipid at mole ratios of 50/10/38.5/1.5. DLin-MC3-DMA exhibits an optimized pKa value that leads todramatically

5、 enhanced potency 1.REFERENCES1. Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-58955